byiShook Opinion
Nov 18, 2024 - 11:10
Neurogene stock collapsed, again, on Monday after the company scrapped the high dose of its experimental Rett syndrome treatment. The post Neurogene — Down 36% — Extends Losses After Side Effect Derails Its Rett Syndrome Drug appeared first on Investor's Business Daily.
Neurogene stock collapsed, again, on Monday after the company scrapped the high dose of its experimental Rett syndrome treatment.
The post Neurogene â Down 36% â Extends Losses After Side Effect Derails Its Rett Syndrome Drug appeared first on Investor's Business Daily.